Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14553894 | 0.95 | USP30 (0.39) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12105709 | 0.91 | USP30 (0.40) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12105710 | 0.89 | GPR119 (0.39) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12110131 | 0.87 | ESR2 (0.42) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12110103 | 0.84 | UTS2R (0.40) | USP30ESR2NR1H2TSHR | |
| SCHEMBL18648634 | 0.82 | PRMT5 (0.36) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12110156 | 0.81 | GPR119 (0.42) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12333228 | 0.81 | TSHR (0.39) | USP30ESR2TSHR | |
| SCHEMBL12333177 | 0.78 | ESR2 (0.36) | USP30PRMT5WDR77GPR119ESR2 | |
| SCHEMBL12110133 | 0.78 | ESR2 (0.41) | USP30PRMT5WDR77GPR119ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | USP30 2185/4885PRMT5 394/4885WDR77 1971/4885 |
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | USP30 2290/4885PRMT5 667/4885WDR77 1904/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | USP30 2185/4885PRMT5 394/4885WDR77 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.